The Evolution of Endocrine Therapy in Breast Cancer

Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer.